87. Defendant Fagron developed and markets drug compounding ingredients, including a transdermal testosterone product it actively promotes as an alternative to Axiron, Androderm, Androgel, and other commercial, FDA-approved products.
88. Fagron Inc. actively markets and promotes compounding instead of FDA approved drugs through its website (fagron.com) and resources such as Fagron Compounding Matters (sharing formulas with pharmacies), Fagron Academy (sharing courses on how to compound and why compounding is better than FDA-approved medications), Fagron Foundation (a marketing attempt to “drive social change” to use compounded, unapproved medications more often), and Fagron TV (a channel devoted to promoting pharmaceutical compounding).
89. As a result of its marketing efforts, Fagron Inc. has done more than just supply compounding supplies for patients who cannot tolerate commercially available medications; it created a market for selling equivalent or similar testosterone products while assuring doctors and consumers of their safety.
|Fagron, Inc. (dft)||ilndce||1:2014-cv-01748||03/14/2014|
|3||Fagron, Inc. (dft)||ilndce||1:2014-cv-04548||367||06/16/2014|